Many tumours are resistant to chemotherapy, either intrinsically or following an initial partial response. A number of pharmacokinetic explanations may account for this, including overexpression of the multidrug resistance gene mdrl, overexpression of drug detoxication enzymes, or alteration of the drug target, for example topoisomerase II isoform. However despite intensive study of drug-target interactions, and drug metabolism, it is clear that in many instances drug resistance is associated with a failure of induction of apoptosis, even after an appropriate triggering event. Since many anti-cancer drugs and ionising radiation damage DNA, the response of the cell in recognising injury and proceeding to repair or apoptosis is of paramount importance (Hickman, 1992; Harrison, 1995) .
Entry to apoptosis is regulated by a number of genes (see Bellamy et al., 1995 for general review), each of which may show abnormal expression or function in cancer. In Rat-I fibroblasts cell cycle arrest or serum deprivation in the presence of constitutive expression of the c-myc oncogene can cause apoptosis (Evan et al., 1992) . By contrast, overexpression of bcl-2 directly inhibits apoptosis in both normal and neoplastic cells (Hockenberry et al., 1990; Sentman et al., 1991; Reed, 1992, 1993; Veis et al., 1993) and prevents c-myc-driven apoptosis (Wagner et al., 1993) . More recently evidence has accumulated implicating the tumoursuppressor gene p53 in an injury-response pathway leading to apoptosis. Thymocytes and myeloid progenitor cells from p53 knockout mice, fail to undergo induced apoptosis in the absence of a wild-type p53 allele following etoposide or ionising radiation treatment but not apoptosis associated with ageing in vitro or non-clastogenic insults such as dexamethasone treatment. (Clarke et al., 1993; Lotem and Sachs, 1993; Lowe et al., 1993a) . Furthermore overexpression of wild-type p53 in a variety of cancer-derived cell lines such as Ml myeloid leukaemia (Yonish-Rouach et al., 1991) , murine erythroleukaemia (Ryan et al., 1993) and HT29 colon carcinoma (Shaw et al., 1992) (Fearon and Vogelstein, 1990) .
In this study we Quantitation of cell number and apoptosis Reference points (three per flask) were used to count directly the number of cells in x 100 field using a 10 x 10 graticule. This permitted sequential counts at 20, 28 and 42 h after plating at 32°C or 37°C. Apoptotic cells adherent to the monolayer were counted at each time point as well as cell number. The apoptotic cells were recognised by virtue of their spherical, highly refractile appearance under phase contrast. These cells showed the classical appearances of apoptosis and were confirmed by electron microscopy and acridine orange fluorescence microscopy (Arends and Harrison, 1994) .
Effects of bleomycin and etoposide Twenty four hours after plating at 37°C cells were either moved to a 32°C incubator or maintained at 37°C for a further 16 h. Etoposide (10, 501M) or bleomycin sulphate (15 pU ml-': 1 U = 1 mg bleomycin A2) were added for 1 h and then washed with phosphate buffered saline (PBS). Controls were performed using equal concentrations of dimethyl sulphoxide (DMSO) or PBS vehicles.
The number of viable and apoptotic cells was counted at intervals up to 50h following drug treatment. The mean number of apoptotic bodies per field was expressed as a percentage of the mean adherent cell number ('percentage apoptosis'). RcGphel32.4 cells were counted 24 h after drug treatment.
Cell cycle analysis Nuclei were isolated and stained with propidium iodide (Vindelov et al., 1983) , and 1 x 104 cells were analysed on an EPICS CS flow cytometry (Coulter). Histogram analysis was performed using the Easy 2 Software. No doublets were seen. Bromodeoxyuridine incorporation analysis was carried out using the Amersham Cell Proliferation Kit (cat no. RPN20).
Results
Clone 6 cells are growth arrested at 32°C Exponentially growing cells were shifted to a 32°C incubator. In three independent experiments cells ceased to show increase in cell number at 32°C (Figure 1 ). There was no inc- (Debbas and White, 1993) respectively. The finding that p53 function is lost in many authentic human and experimentally induced animal tumours has led to the assumption that p53 loss of function is causally associated with resistance to anti-cancer therapy (Lowe et al., 1993b) . In this study we have addressed the importance of p53 status on the sensitivity of cells to apoptosis induced by two anti-cancer drugs.
We have shown here, in a fibroblast cellTine transformed with activated Ha-ras and temperature-sensitive p53 transgenes that wild-type p53 leads to GI arrest and at the same time resistance to the DNA damaging agents bleomycin and etoposide. By contrast, in the presence of mutant conformation p53, cells underwent apoptosis associated with a relative accumulation in G2/M, a common response to DNA injury in yeast and mammalian cells (Hartwell and Weinert, 1989) .
We were unable to produce a GO/GI arrest in Clone 6 cells at 37°C by either mimosine treatment or serum starvation as these treatments caused the death of the cultures. We were thus unable to show directly that a growth arrest in GO/GI, independent of p53, was protective against DNA damage.
Our findings apparently contrast with published work in which temperature-sensitive p53 was expressed in the Ml myeloid leukaemic (Ml; Yonish-Rouach et al.,1993) (Diller et al., 1990; Mercer et al., 1990; Michalovitz et al., 1990; Kastan et al., 1992) . While bleomycin and etoposide maximally kill cells in S-phase, where replication forks are forced to negotiate either cleaved complex / double strand breaks (etoposide; Bae et al., 1988) or double-strand breaks resulting from free-radical attack (bleomycin; Kuo, 1981), they can damage and kill cells in GO/GI (Roy et al., 1992; Clarke et al., 1993; Evans et al., 1994) . In cell lines derived from clinically sensitive human tumours, DNA injury-induced wild-type p53 was held to be responsible for decreased clonogenicity following ionising radiation and this effect could be reversed by transfection of a dominant negative mutant p53. (McIlwrath et al., 1994) .
The simplest explanation of our data is that the GI arrest mediated by p53 facilitates survival of ras-transformed fibroblasts by allowing effective DNA repair and prevents entry into S-phase, a stage when cells are often most susceptible to DNA damage.
Depending upon the cell system chosen, induction of p53 can cause either GI arrest, apoptosis or both apoptosis and GI arrest (Michalovitz et al., 1990; Debbas and White, 1993; Ryan et al., 1993; Yonish-Rouach et al., 1993; Wu and Levine, 1994) . The mechanisms by which decisions are taken that favour any of these end points are poorly defined but these decisions can be affected by specific growth factors (Yonish-Rouach et al., 1991; Gottleib et al., 1994; Canman et al., 1995 
